Scarica l'app Stockscreener
14.91
6.12%
0.86
Pre-mercato:
13.16
-1.75
-11.74%
Precedente Chiudi:
$14.05
Aprire:
$13.97
Volume 24 ore:
896.80K
Relative Volume:
0.43
Capitalizzazione di mercato:
$726.76M
Reddito:
$15.84M
Utile/perdita netta:
$-308.48M
Rapporto P/E:
-2.3009
EPS:
-6.48
Flusso di cassa netto:
$-153.08M
1 W Prestazione:
+12.70%
1M Prestazione:
-12.19%
6M Prestazione:
+92.64%
1 anno Prestazione:
+168.65%
Intervallo 1D:
$13.70
$15.18
Intervallo di 1 settimana:
$13.33
$15.18
Portata 52W:
$3.73
$19.18
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
14.91 | 726.76M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
uniQure (NASDAQ:QURE) Earns "Outperform" Rating from Royal Bank of Canada - MarketBeat
(QURE) Technical Pivots with Risk Controls - Stock Traders Daily
Hemophilia B Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharma, CSL Behring, uniQure, Novo Nordisk - The Globe and Mail
Sanders Morris Harris LLC Increases Stake in uniQure (NASDAQ:QURE) - MarketBeat
Short Interest in uniQure (NASDAQ:QURE) Declines By 21.2% - MarketBeat
Here’s Why uniQure N.V. (QURE) Is Skyrocketing - MSN
Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025? - Insider Monkey
(QURE) Trading Signals - Stock Traders Daily
uniQure sets $17 share price for $75 million offering By Investing.com - Investing.com Nigeria
uniQure (NASDAQ:QURE) Receives $33.88 Consensus Target Price from Brokerages - MarketBeat
uniQure (NASDAQ:QURE) Sees Strong Trading VolumeStill a Buy? - MarketBeat
uniQure sets $17 share price for $75 million offering - Investing.com India
uniQure Announces Pricing of its Public Offering - The Manila Times
uniQure Prices $75 Million Public Offering at $17.00 Per Share to Boost Growth Capital - StockTitan
uniQure Announces Proposed Public Offering - The Manila Times
uniQure Announces Public Offering of Ordinary Shares and Pre-Funded Warrants - StockTitan
UniQure stock soars to 52-week high, hits $18.5 amid robust gains - Investing.com Canada
uniQure (NASDAQ:QURE) Sets New 1-Year HighHere's What Happened - MarketBeat
uniQure (NASDAQ:QURE) Shares Down 3.5%What's Next? - MarketBeat
uniQure (NASDAQ:QURE) Shares Gap DownHere's What Happened - MarketBeat
Uniqure stock soars to 52-week high, reaches $18.14 By Investing.com - Investing.com Canada
Uniqure stock soars to 52-week high, reaches $18.14 - Investing.com India
How the (QURE) price action is used to our Advantage - Stock Traders Daily
uniQure (NASDAQ:QURE) Shares Gap UpStill a Buy? - MarketBeat
UniQure stock soars to 52-week high, hits $17.75 amid robust gains By Investing.com - Investing.com South Africa
UniQure stock soars to 52-week high, hits $17.75 amid robust gains - Investing.com Nigeria
Franklin Resources Inc. Makes New $7.36 Million Investment in uniQure (NASDAQ:QURE) - MarketBeat
uniQure (NASDAQ:QURE) Trading 5.8% Higher Following Analyst Upgrade - MarketBeat
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug - MSN
uniQure (NASDAQ:QURE) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
CSL and uniQure Win 2023 Prix Galien USA Award - GuruFocus.com
57,333 Shares in uniQure (NASDAQ:QURE) Purchased by Y Intercept Hong Kong Ltd - MarketBeat
Around the Helix: Cell and Gene Therapy Company Updates – December 18, 2024 - CGTLive™
uniQure price target raised to $32 from $12 at Stifel - Yahoo Finance
uniQure (NASDAQ:QURE) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
uniQure (NASDAQ:QURE) Price Target Raised to $32.00 at Stifel Nicolaus - MarketBeat
uniQure (NASDAQ:QURE) Shares Acquired by Fmr LLC - MarketBeat
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? - Yahoo Finance
uniQure (NASDAQ:QURE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):